OPUS GENETICS INC

Opus Genetics stock plunges 7% amid leadership exit, pending 10‑K and mounting doubts over its science and financial health.

Opus Genetics shares rise 2.74 % to $3.82, reaching a $333.6 M market cap – a clinical‑stage eye‑health biotech making strides in ophthalmic therapies.

Opus Genetics (IRD) rallies near its 200‑day SMA with strong clinical momentum, flexible capital, and a promising ophthalmic pipeline—an attractive biotech play for investors.